In today’s recent session, 0.5 million shares of the Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) have been traded, and its beta is 1.52. Most recently the company’s share price was $18.12, and it changed around -$0.91 or -4.78% from the last close, which brings the market valuation of the company to $2.39B. CNTA at last check was trading at a discount to its 52-week high of $19.09, offering almost -5.35% off that amount. The share price’s 52-week low was $7.38, which indicates that the recent value has risen by an impressive 59.27% since then. We note from Centessa Pharmaceuticals plc ADR’s average daily trading volume that its 10-day average is 0.82 million shares, with the 3-month average coming to 661.21K.
Centessa Pharmaceuticals plc ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CNTA as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Centessa Pharmaceuticals plc ADR is expected to report earnings per share of -0.35 for the current quarter.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information
Instantly CNTA has been showing red trend so far today with a performance of -4.78% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 19.09 on recent trading dayincreased the stock’s daily price by 5.08%. The company’s shares are currently up 8.18% year-to-date, but still up 7.22% over the last five days. On the other hand, Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) is 12.55% up in the 30-day period. We can see from the shorts that 3.29 million shares have been sold at a short interest cover period of 6.42 day(s).
The consensus price target as assigned by Wall Street analysts is $23, which translates to bulls needing to increase their stock price by 21.22% from its current value. Analyst projections state that CNTA is forecast to be at a low of $19 and a high of $28.
Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts
The year-over-year growth rate is expected to be -100.00%, down from the previous year.
Analysts predict that the company’s current quarter sales will drop, forecast at -100.00%. Forecasts for the next quarter put sales growth at 0.00%.
Centessa Pharmaceuticals plc ADR earnings are expected to increase by 2.97% in 2025, but the outlook is negative -3.20% per year for the next five years.
CNTA Dividends
Centessa Pharmaceuticals plc ADR’s next quarterly earnings report is expected to be released in March.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.29% of Centessa Pharmaceuticals plc ADR shares, and 92.58% of them are in the hands of institutional investors. The stock currently has a share float of 93.79%. Centessa Pharmaceuticals plc ADR stock is held by 130.0 institutions, with MEDICXI VENTURES MANAGEMENT (JERSEY) LTD being the largest institutional investor. By 2024-06-30, it held 19.9856% of the shares, which is about 19.96 million shares worth $180.27 million.
GENERAL ATLANTIC, L.P., with 9.6927% or 9.68 million shares worth $87.43 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Select Portfolios – Biotechnology and Price (T.Rowe) Health Sciences Fund were the top two Mutual Funds as of Nov 30, 2024. The former held 2.98 shares worth $53.9 million, making up 2.26% of all outstanding shares. On the other hand, Price (T.Rowe) Health Sciences Fund held roughly 2.95 shares worth around $53.37 million, which represents about 2.24% of the total shares outstanding.
